The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
Official Title: Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
Study ID: NCT00849875
Brief Summary: The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when given in combination with dacarbazine and evaluate the safety of this combination.
Detailed Description: This Protocol Posting has been updated following amendment 3, dated 16 October 2009. The sections impacted are : * Enrollment, number of subjects * Outcome measures * Exclusion criteria
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
GSK Investigational Site, Brussels, , Belgium
GSK Investigational Site, Brussel, , Belgium
GSK Investigational Site, Bruxelles, , Belgium
GSK Investigational Site, Liège, , Belgium
GSK Investigational Site, Roeselare, , Belgium
GSK Investigational Site, Yvoir, , Belgium
GSK Investigational Site, Caen, , France
GSK Investigational Site, Lille, , France
GSK Investigational Site, Marseille Cedex 5, , France
GSK Investigational Site, Nantes, , France
GSK Investigational Site, Paris Cedex 10, , France
GSK Investigational Site, Paris, , France
GSK Investigational Site, Reims, , France
GSK Investigational Site, Villejuif, , France
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR